- Analysts predict a potential 16% upside for Medtronic (MDT, Financial) based on the average price target.
- The company faces potential impacts from upcoming global tariffs.
- Medtronic is rated as "Outperform" with a GF Value estimate suggesting a 17.38% increase from the current price.
Medtronic (MDT) stands out as a key player in the healthcare sector, yet it faces potential challenges from new global tariff policies. Barclays analysts highlight these impending changes, particularly for companies dependent on international supply chains, which may see tariff exposure becoming a crucial factor in industry differentiation.
Wall Street Analysts Forecast
According to the insights of 28 analysts, Medtronic PLC (MDT, Financial) carries a one-year average price target of $95.91, with projections reaching as high as $112.46 and a low estimate of $85.00. This average target reflects an anticipated upside of 15.97% from the current market price of $82.70. For a more comprehensive breakdown of these estimates, visit the Medtronic PLC (MDT) Forecast page.
The consensus among 34 brokerage firms points to an average brokerage recommendation of 2.5 for Medtronic PLC (MDT, Financial), categorizing it as "Outperform." This rating scale spans from 1, indicating a Strong Buy, to 5, which denotes a Sell recommendation.
Delving into GuruFocus metrics, the estimated GF Value for Medtronic PLC (MDT, Financial) is pegged at $97.07 for the coming year. This suggests a potential upside of 17.38% from the present stock price of $82.7. The GF Value is derived from the stock's historical trading multiples, as well as its past and anticipated future business performance. For further detailed analysis, visit the Medtronic PLC (MDT) Summary page.
